Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3 CAR T Cells in Children and Young Adults With Relapsed or Refractory Solid Tumors
NCT07358260Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B7-H3 UCAR-T in Pediatric solid tumor (PST) and neuroblastoma. Primary endpoints: Manufacturing Success Rate of Autologous B7-H3.CD28Z CART Cells at Day 0 and Maximum Tolerated Dose at 28 days. Started Aug 2026; status: recruiting.
02
Drugs
B7-H3 UCAR-T
03
Conditions
Pediatric solid tumor (PST)neuroblastoma
Beyond the preview
Go deeper on NCT07358260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358260.